Groups Representing Patients, Healthcare Professionals and Pharmaceutical Industry Author New Principle on Use of AI In Healthcare
Article content
GENEVA — Six leading international organizations representing patients, physicians, pharmacists, nurses, hospitals, and the pharmaceutical industry have today adopted the first joint ethical principle in the healthcare industry on the responsible use of health data and technology, including artificial intelligence.
Article content
The new principle joins the International Consensus Framework for Ethical Collaboration in Health, guiding ethical collaboration across bodies representing patients, physicians, pharmacists, nurses, hospitals, and the pharmaceutical industry.
Article content
The new principle joins the International Consensus Framework for Ethical Collaboration (ICF), a longstanding principles-based voluntary agreement that guides ethical collaboration across these major healthcare bodies, working together to deliver high quality care for patients.
Article content
The ICF was established in 2014 as a global platform to ensure that relationships across the health ecosystem are grounded in ethical, transparent, and responsible decision-making. It unites six leading health bodies representing patient organizations, healthcare professionals, and the pharmaceutical industry.
Article content
The founding principles of the ICF focus on prioritizing patients; supporting ethical research and innovation; ensuring independence and ethical conduct; and promoting transparency and accountability.
Article content
The new fifth principle focuses on autonomy, data stewardship, and shared accountability in the use of health data. This reflects the growing importance of digital health and AI, and the need for ethical considerations to evolve alongside scientific innovation.
Article content
'No single hospital or stakeholder can navigate today's rapid advances in health data and technology alone,' said Ronald Lavater, CEO of the International Hospital Federation. 'The ICF enables collective action, empowering global health leaders to build trusted partnerships that unlock the full potential of ethical, person-centered innovation.'
Article content
'Data and technology may evolve care delivery, but ethics guides our why, how and for whom,' said Howard Catton, CEO of the International Council of Nurses. 'This principle affirms the enduring importance of trust, compassion, and dignity — values nurses uphold every day across health systems worldwide.'
Article content
Patient voices are central to the adoption of this principle. 'This new principle is a major step forward in safeguarding the rights of patients and people with lived experience in the digital age,' said Dani Mothci, CEO of the International Alliance of Patients' Organizations. 'As a founding member of the ICF, IAPO welcomes the clear ethical commitment around autonomy, data stewardship, and accountability highlighting focus on putting patients first. To make this a reality, we encourage patient organizations to actively engage with this principle and ensure its implementation reflects real-world patient experiences.'
Article content
'Ethics is the cornerstone of effective global health policy. It ensures that decisions are guided by fairness, respect, and accountability. The World Medical Association believes that ethical collaboration is essential to building resilient health systems and delivering better care to all, especially the most vulnerable,' said Dr. Ashok Philip, President of the World Medical Association.
Article content
Paul Sinclair, President of the International Pharmaceutical Federation, called on pharmacy professionals to embrace the new principle: 'FIP supports ethical and responsible decision making, which involves pharmacy practitioners in relation to patients, healthcare professionals, and the pharmaceutical sector to ensure high-quality care. I invite all our members to adopt and adapt this framework at the country and regional levels of practice.'
Article content
David Reddy, Director General of the International Federation of Pharmaceutical Manufacturers and Associations, echoed the call for collective responsibility: 'For the past decade, the ICF has fostered stronger alliances and shared values between key partners involved in healthcare delivery, through sustained engagement on emerging ethical challenges. Today, by integrating a new principle on digital health and AI, we're echoing a growing consensus: as innovation accelerates, ethical collaboration must evolve in tandem. Our focus is on delivering for patients — first and always.'
Article content
Established in 2014, the
Article content
International Consensus Framework for Ethical Collaboration
Article content
is the only global platform of its kind that brings together patients' organizations, healthcare professionals, and the pharmaceutical industry in support of high-quality, patient-centered care. The Framework is jointly supported by six leading bodies – the
Article content
,
Article content
,
Article content
IFPMA
Article content
,
Article content
FIP
Article content
,
Article content
WMA
Article content
, and
Article content
IHF
Article content
– all united by a shared commitment to ensuring that relationships across the health ecosystem are grounded in ethical, transparent, and responsible decision-making. The Consensus Framework is a living document and is open to other stakeholders in life sciences and healthcare delivery, who are encouraged to endorse and contribute to its evolution. It is guided by four founding principles: put patients first; support ethical research and innovation; ensure independence and ethical conduct; promote transparency and accountability. In 2025, the Framework was expanded to include a fifth principle: uphold responsible use of health data and technology. This reflects the growing importance of digital health and AI, and the need for ethics to evolve alongside innovation.
Article content
Article content
Article content
Article content
Contacts
Article content
Media contacts
Article content
Article content
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
a day ago
- Globe and Mail
FUE Hair Transplant Clinic London Launches New Website to Enhance Patient Experience and Education
London, UK - June 27, 2025 - FUE Hair Transplant Clinic London is pleased to announce the launch of its newly designed website, designed to provide patients with a seamless, informative, and user-friendly experience. The new site reflects the clinic's commitment to delivering high-quality, surgeon-led hair transplant procedures while prioritising education and accessibility for both new and existing patients. The redesigned website ( features an intuitive layout, faster navigation, and comprehensive resources about hair restoration treatments, including Follicular Unit Extraction (FUE), one of the most advanced and minimally invasive hair transplant techniques available today. Prospective patients can now easily access detailed guides on the FUE procedure, explore before-and-after galleries, and book confidential consultations directly with leading UK-trained surgeons. The site also features a new blog section, offering expert insights into hair loss, recovery timelines, treatment costs, and the science behind successful transplants. 'Our goal was to create a digital experience that mirrors the quality of care we provide in-clinic,' said the Lead Surgeon at FUE Hair Transplant Clinic London. 'Many of our patients begin their journey online, so it was crucial to build a platform that's educational, trustworthy, and easy to navigate. We want people to feel empowered when making one of the most personal decisions about their appearance.' Visitors can explore real patient stories, understand pricing with no hidden fees, and get clear information about what to expect before, during, and after their procedure. The launch of the new website marks a key step in FUE Hair Transplant Clinic London's mission to make hair restoration more accessible, personalised, and results-driven for individuals experiencing hair loss. Media Contact Company Name: Press featured Contact Person: Maxwell Pierce Email: Send Email Country: United Kingdom Website:


Globe and Mail
a day ago
- Globe and Mail
Novo Nordisk Stock (NVO) Inches Higher Despite More U.K. Weight Jab Concerns
Shares in pharmaceutical giant Novo Nordisk (NVO) edged higher today despite more pressure from health officials in the U.K. about the safety of weight-loss drugs. Confident Investing Starts Here: Pancreas Link The U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) said today that it will investigate whether there is a link between weight-loss injections and acute inflammation of the pancreas. Indeed, they are asking people on weight-loss drugs who have been hospitalized by acute pancreatitis to get in touch. This comes after data from MHRA which showed that since the drugs were licensed, there have been hundreds of reported cases of acute and chronic pancreatitis among people taking GLP-1 medicines. That includes 113 cases and one death linked to semaglutide, which is the active ingredient in Novo Nordisk's Wegovy and Ozempic weight-loss injections. Meanwhile, 181 cases, with five deaths, were reported linked to tirzepatide, which is the active ingredient in Eli Lilly's (LLY) rival Mounjaro treatment. MHRA chief safety officer Dr Alison Cave said the aim was to 'better predict those most at risk of adverse reactions.' Think Twice This follows a warning earlier this month from the MHRA to pregnant women that it is unclear whether weight-loss injections could harm unborn babies. Russ Mould, investment director at AJ Bell, said this regular commentary on the side effects of injectable weight-loss drugs could make some patients think twice about using them. 'Reports of pancreas-related illnesses in a tiny number of cases could yet attract regulatory scrutiny,' he added. In the UK, the injections are only available through the state-run National Health Service, but people are still accessing them via sellers on social media or beauty salons. The demand is expected to be there. Globally, about 3.8 billion people over 25 and just under 750 million children and young people will be overweight or obese by 2050. Is NVO a Good Stock to Buy Now? On TipRanks, NVO has a Moderate Buy consensus based on 4 Buy, 3 Hold and 1 Sell rating. Its highest price target is $142.56. NVO stock's consensus price target is $94.79 implying a 40.32% upside. See more NVO analyst ratings


CBC
2 days ago
- CBC
Lung transplant patients say expenses have left them in financial ruin
Nova Scotia patients want the government to provide more money to help those who have to leave the province for the life-saving care. The CBC's Carolyn Ray has the story.